Softwr

Healthcare · head to head

Clue vs Paige

Clue logo

Clue

Healthcare

Period and cycle tracking app owned by German company Biowink, positioned around science based tracking and a published stance against sharing data with law enforcement

From
Free
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Only Clue has a free tier, so it costs nothing to try first.
  • Each has a real cost: Clue clues stated policy on not sharing data with law enforcement without a valid legal process is the companys own published position and legal interpretation, not an independent guarantee, and it can still be compelled to comply with a legally binding request under EU or other applicable law.; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Clue covers Cycle and symptom tracking, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Clue and Paige actually diverge.

Attributes where Clue and Paige differ
AttributeCluePaige
Starting priceFreeOn request
Pricing modelFree with a Plus subscriptionquote
Free tierYesNo
PlatformsiOS, AndroidWeb, Cloud, On-premise

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Clue

  • Cycle and symptom tracking
  • Cycle insights and patterns
  • Research partnerships
  • EU-based data hosting
  • Fertility and conception mode
  • Perimenopause and other life stage tracking

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Clue

  • Someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given Clues EU basis and published stance on law enforcement requestsnot Paige
  • A user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community contentnot Paige
  • A buyer comparing Clue directly against Flo on current published privacy policy language before choosing which app to trustnot Paige
  • Someone tracking perimenopause or other non-standard cycle stages that some period apps do not support wellnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Clue
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Clue
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Clue
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Clue

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Clue

  • Clues stated policy on not sharing data with law enforcement without a valid legal process is the companys own published position and legal interpretation, not an independent guarantee, and it can still be compelled to comply with a legally binding request under EU or other applicable law.
  • Deeper cycle insights and predictions, the features most likely to justify tracking in the first place, are gated behind the Clue Plus subscription rather than fully free.
  • Being a smaller company than some competitors, Clue has less capital and legal resource to contest large-scale legal requests than a larger, better-funded rival might, despite its stated intent to do so.
  • Research partnerships using anonymised user data, while opt-in, still mean user-derived data can be used in ways beyond direct app functionality, and users should check current consent settings.
  • Cycle predictions rely on self-reported data and general population models, so accuracy for irregular cycles or specific medical conditions remains limited regardless of which app is used.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Clue

Free
  • Clue Plus$9.99/month
    • Free tier covers core cycle tracking, logging and basic predictions
    • Clue Plus adds deeper cycle insights, extended predictions and personalised content
    • Annual Plus plans typically offered at a lower effective monthly rate

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Clue if

  • You need cycle and symptom tracking.
  • You want to start without paying.
  • You work on iOS, Android.
  • You also want cycle insights and patterns.
Clue review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Clue or Paige better?
Neither clearly leads. Clue starts at Free and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Clue or Paige?
Clue has a free tier; the other does not. Paid plans start at Free for Clue and On request for Paige.
Does Clue or Paige run on more platforms?
Clue runs on iOS, Android. Paige runs on Web, Cloud, On-premise.
Can I use Clue for free?
Yes. Clue has a free tier, so you can try it without paying. Paige starts at On request.
What is Clue best used for?
Clue is most often used for someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given clues eu basis and published stance on law enforcement requests, a user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community content, a buyer comparing clue directly against flo on current published privacy policy language before choosing which app to trust, someone tracking perimenopause or other non-standard cycle stages that some period apps do not support well. Of those, someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given clues eu basis and published stance on law enforcement requests and a user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community content are not what Paige is typically brought in for.
What can Clue do that Paige cannot?
Clue covers Cycle and symptom tracking, Cycle insights and patterns, Research partnerships, EU-based data hosting. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Clue: Does Clue share data with law enforcement?

Clue publishes a policy stating it does not share health data with law enforcement or public authorities without a legally binding request and states it will challenge requests it considers improper. This is the companys stated position; verify the current policy directly for specifics.

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Clue: Why does Clue emphasise being an EU company?

Clue operates under EU GDPR data protection rules and states this legal basis makes it harder for authorities outside the EU, including US authorities, to compel data disclosure than for a company based in the US.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Clue: Is Clue free?

Core cycle tracking, logging and basic predictions are free. Deeper insights and extended predictions require Clue Plus.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Clue

More on Paige

Keep looking

Other head to heads